Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.
Código da empresaMTSR
Nome da EmpresaMetsera Inc
Data de listagemJan 31, 2025
CEOMr. Christopher Whitten Bernard
Número de funcionários74
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 31
Endereço3 World Trade Center
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal10007
Telefone12127846595
Sitehttps://metsera.com/
Código da empresaMTSR
Data de listagemJan 31, 2025
CEOMr. Christopher Whitten Bernard
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados